Compositions and methods for treating thyroid disease

Abstract

The present disclosure relates to a compound and method of administering such compound for treating a patient suffering from thyroid disease and various thyroid-related disorders, including hyperthyroid and hypothyroid. The unique combination of the composition is preferably administered orally. The composition is preferably comprised of at least selenium, zinc, iodine, manganese, molybdenum, ashwaganda root powder, polygonum root extract, a digestive enzyme such as DPP-IV, L-tyrosine and mullein leaf, in pre-determined amounts. The composition can further comprise a palliative agent, and can be provided in the form of a capsule or tablet.

What is claimed is: 
     
         1 . A method for treating a thyroid disease comprising: administering an effective amount of a composition to a patient suffering from the thyroid disease, wherein the composition comprises:
 0.5 to 3.5 mg of B6;   10 to 100 mcg, of B12;   300 to 700 mcg of iodine;   50 to 250 mcg of selenium;   4 to 16 mg of zinc;   0.5 to 3.5 of manganese;   25 to 125 mcg to molybdenum;   300 to 600 mg of ashwaganda root powder;   50 to 170 mg of an extract selected from the group consisting of polygonum root extract, a grape seed extract, or combinations thereof; and   100 to 800 mg of at least one digestive enzyme.   
     
     
         2 . The method of  claim 1 , wherein the thyroid disease is selected from the group consisting of hyperthyroid, and hypothyroid. 
     
     
         3 . The method of  claim 1 , wherein the composition is administered orally in the form of a capsule. 
     
     
         4 . The method of  claim 3 , wherein the method further comprises administering between 1 and 3 capsules of the composition to the patient per day. 
     
     
         5 . The method of  claim 1 , wherein the composition administered to the patient further comprises 40 to 110 mg of L-Tyrosine. 
     
     
         6 . The method of  claim 5 , wherein the composition administered to the patient further comprises 20 to 80 mg of mullein leaf. 
     
     
         7 . The method of  claim 6 , wherein the digestive enzyme is DPP-IV. 
     
     
         8 . A method for treating a thyroid disease by administering to a patient in need thereof a composition, wherein the composition comprises:
 about 2 mg of B6;   about 90 mcg of B12;   about 500 mcg of iodine;   about 150 mcg of selenium;   about 10 mg of zinc;   about 2 mg of manganese;   about 75 mcg of molybdenum;   about 450 mg of ashwagandha root powder;   about 102 mg of polygonum root extract;   about 200 mg of DPP-IV;   about 75 mg of L-Tyrosine; and   about 50 mg of mullein leaf   
     
     
         9 . The method of  claim 8 , wherein the B12 administered to the patient is in the form of methylcobalamin. 
     
     
         10 . The method of  claim 8 , wherein the composition administered to the patient further comprises calcium phosphate. 
     
     
         11 . The method of  claim 8 , wherein the composition administered to the patient further comprises copper gluconate. 
     
     
         12 . The method of  claim 8 , wherein the composition administered to the patient further comprises hydroxypropyl methylcellulose. 
     
     
         13 . The method of  claim 8 , wherein the composition administered to the patient does not comprise additives selected from the group consisting of gluten, wheat, egg, peanuts, tree nuts, dairy, sugar, corn, soy, artificial colors, preservatives, fish and shellfish. 
     
     
         14 . The method of  claim 8 , wherein the composition administered to the patient further comprises at least one palatability agent. 
     
     
         15 . The method of  claim 14 , wherein the palatability agent is selected from the group consisting of plant oils, plant hydrolysates, yeast, and yeast hydrolysates. 
     
     
         16 . The method of  claim 15 , wherein the thyroid disease is selected from the group consisting of hyperthyroid, and hypothyroid. 
     
     
         17 . The method of  claim 16 , wherein the composition is administered orally in the form of a capsule. 
     
     
         18 . The method of  claim 17 , wherein the method further comprises administering between 1 and 3 capsules of the composition to the patient per day. 
     
     
         19 . The method of  claim 16 , wherein the composition is administered to the patient as a dietary supplement.